Moderna, Inc. MRNA
198.88
4.06
2.08%
as of 25 Sep
- Market cap
- $78.8B
- P/E
- 0.0×
Follow MRNA
Indexes
indicate stock being part of an index
Moderna, Inc. (MRNA) Net margin
Moderna, Inc.'s net margin over the twelve months to 30 June 2026 was −141.4%, up 3.7 percentage points from fiscal 2025 (−145.2%). Over the past ten years it has ranged from −856.7% (fiscal 2019) to 66.1% (fiscal 2021); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −145.2% | (35.12) |
| FY2024 | −110.0% | (41.20) |
| FY2023 | −68.8% | (112.25) |
| FY2022 | 43.4% | (22.65) |
| FY2021 | 66.1% | 159.09 |
| FY2020 | −93.0% | 763.64 |
| FY2019 | −856.7% | (559.15) |
| FY2018 | −297.5% | (166.42) |
| FY2017 | −131.1% | 81.37 |
| FY2016 | −212.5% | — |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −539.3% | (194.07) |
| Mar 2026 | −345.2% | (223.41) |
| Dec 2025 | −121.8% | (102.14) |
| Sep 2025 | −19.7% | 561.30 |
| 30 more quarters | Free account |
Against its own ten years
Low −856.7%
High 66.1%
Ten-year median
−120.6%
Current reading's percentile
40
Net margin against peers
| Company | Net margin |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | 35.0% |
| ARGX argenex SE compare | 32.2% |
| RPRX Royalty Pharma PLC compare | 32.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 27.9% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 16.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.7% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| INSM Insmed, Inc. compare | −76.9% |
| MRNA Moderna, Inc. | −141.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on MRNA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement